Forecast for a SARS-CoV-2 vaccine candidate showing a 70% or better efficacy

by Dan Sluder, Tamay Besiroglu, Juan Cambeiro, Thomas McAndrew

Jul 07, 2020

SARS-CoV-2-Vaccine

model type: *crowdSource*
survey date: *6/24/2020*
prediction type: *date*
10th percentile: *12/6/2020*
25th percentile: *4/6/2021*
median: *9/22/2021*
75th percentile: *8/7/2022*
90th percentile: *6/15/2023*
range min: *6/14/2020*
range max: *6/14/2023*



Background:

The Countermeasures Surveys is a six-month long research project intended to generate and aggregate predictions regarding the development of vaccines and therapeutic interventions for SARS-CoV-2 and COVID-19, respectively. We solicit predictions each month from a large team consisting of subject-matter experts as well as top generalist forecasters with established track-records in human-judgment forecasting. The methods used for prediction solicitation and aggregation are discussed in [1].

Question:

When will a SARS-CoV-2 vaccine candidate demonstrate 70% or better efficacy?

Resolution:

Resolves as the date when the first peer-reviewed research article of a phase III randomized controlled trial publishes a median estimate of the absolute vaccine efficacy of at least 70%.

Summary of Predictions:

The expert median prediction that a SARS-CoV-2 vaccine candidate will demonstrate 70% or better efficacy is September 2021 (80% CI: December 2020, June 2023 or later). Experts Assign a probability of 12% to this occuring after June 15th 2023.

References:

1) https://outbreak.flashpub.io/pub/outbreak-modeling-method-of-prediction-aggregation_7ad8f40a-dbf2-4e
2) https://github.com/mcandrewlab/vaccinceAndTherapeuticsCrowd